Back

Identification and Interaction Analysis of Molecular Markers in Pancreatic Ductal Adenocarcinoma by Integrated Bioinformatics Analysis and Molecular Docking Experiments

Vastrad, B. M.; Vastrad, C. M.; Tengli, A. R.

2020-12-23 genetic and genomic medicine
10.1101/2020.12.20.20248601 medRxiv
Show abstract

The current investigation aimed to mine therapeutic molecular targets that play an key part in the advancement of pancreatic ductal adenocarcinoma (PDAC). The expression profiling by high throughput sequencing dataset profile GSE133684 dataset was downloaded from the Gene Expression Omnibus (GEO) database. Limma package of R was used to identify differentially expressed genes (DEGs). Functional enrichment analysis of DEGs were performed. Protein-protein interaction (PPI) networks of the DEGs were constructed. An integrated gene regulatory network was built including DEGs, microRNAs (miRNAs), and transcription factors. Furthermore, consistent hub genes were further validated. Molecular docking experiment was conducted. A total of 463 DEGs (232 up regulated and 231 down regulated genes) were identified between very early PDAC and normal control samples. The results of Functional enrichment analysis revealed that the DEGs were significantly enriched in vesicle organization, secretory vesicle, protein dimerization activity, lymphocyte activation, cell surface, transferase activity, transferring phosphorus-containing groups, hemostasis and adaptive immune system. The PPI network and gene regulatory network of up regulated genes and down regulated genes were established, and hub genes were identified. The expression of hub genes (CCNB1, FHL2, HLA-DPA1 and TUBB1) were also validated to be differentially expressed among PDAC and normal control samples. Molecular docking experiment predicted the novel inhibitory molecules for CCNB1 and FHL2. The identification of hub genes in PDAC enhances our understanding of the molecular mechanisms underlying the progression of this disease. These genes may be potential diagnostic biomarkers and/or therapeutic molecular targets in patients with PDAC.

Matching journals

The top 10 journals account for 50% of the predicted probability mass.

1
Scientific Reports
3102 papers in training set
Top 9%
8.7%
2
Frontiers in Oncology
95 papers in training set
Top 0.4%
7.0%
3
PLOS ONE
4510 papers in training set
Top 26%
6.6%
4
Virologica Sinica
10 papers in training set
Top 0.1%
5.0%
5
Genomics
60 papers in training set
Top 0.1%
5.0%
6
Heliyon
146 papers in training set
Top 0.3%
3.8%
7
Informatics in Medicine Unlocked
21 papers in training set
Top 0.1%
3.7%
8
International Journal of Molecular Sciences
453 papers in training set
Top 2%
3.7%
9
Frontiers in Molecular Biosciences
100 papers in training set
Top 0.3%
3.7%
10
Frontiers in Pharmacology
100 papers in training set
Top 1%
2.8%
50% of probability mass above
11
Biomedicines
66 papers in training set
Top 0.3%
2.7%
12
Frontiers in Genetics
197 papers in training set
Top 3%
2.1%
13
Bioscience Reports
25 papers in training set
Top 0.3%
2.1%
14
Frontiers in Immunology
586 papers in training set
Top 4%
1.8%
15
BioMed Research International
25 papers in training set
Top 1%
1.8%
16
Gene Reports
13 papers in training set
Top 0.3%
1.7%
17
Aging
69 papers in training set
Top 2%
1.5%
18
Translational Oncology
18 papers in training set
Top 0.2%
1.4%
19
Computers in Biology and Medicine
120 papers in training set
Top 3%
1.3%
20
Cell & Bioscience
14 papers in training set
Top 0.1%
1.1%
21
Cells
232 papers in training set
Top 4%
1.0%
22
Frontiers in Microbiology
375 papers in training set
Top 7%
1.0%
23
Archives of Clinical and Biomedical Research
28 papers in training set
Top 1%
1.0%
24
Cell Death & Disease
126 papers in training set
Top 2%
0.9%
25
Cell Proliferation
12 papers in training set
Top 0.3%
0.9%
26
PeerJ
261 papers in training set
Top 12%
0.9%
27
Biology
43 papers in training set
Top 2%
0.9%
28
Signal Transduction and Targeted Therapy
29 papers in training set
Top 1%
0.9%
29
eLife
5422 papers in training set
Top 54%
0.8%
30
BMC Cancer
52 papers in training set
Top 2%
0.8%